BSCM
BMY.RT

Berry Street Capital Management’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Berry Street Capital Management’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-425,000
Closed -$293K – 153
2020
Q4 		$293K Buy
+425,000
New +$905K 0.04% 73

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.82B AUM
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return

Berry Street Capital Management's BMY.RT Position: Q1 2021 in Review

Berry Street Capital Management sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 425,000 shares — an estimated $293K sold.

Berry Street Capital Management first reported a position in BMY.RT in Q4 2020 and held it in 1 quarter. The position peaked at $293K in Q4 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Berry Street Capital Management reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Berry Street Capital Management sold 425,000 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $293K.
  • Berry Street Capital Management first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2020 and held it in 1 quarter.
  • Berry Street Capital Management's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $293K in Q4 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Berry Street Capital Management's 13F filing for Q1 2021, filed 14 May 2021.